Loading
A phase 2/3 trial testing HLX43 in non-small-cell lung cancer, now recruiting.
A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer is a phase 2/3 interventional study registered as NCT07459751, led by Shanghai Henlius Biotech, and recruiting on the registry. Official title: A Randomised, Open-Label, Multi-centre, Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) Monotherapy or HLX43 in Combination With HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody Injection) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC). Planned enrolment is 706 participants (estimated). The study started in 2026-05-27 and primary completion is expected in 2030-01-15. No results have been posted on ClinicalTrials.gov.
Shares HLX43, Shanghai Henlius Biotech.
Shares HLX43, Shanghai Henlius Biotech.
Shares Shanghai Henlius Biotech, Non-small-cell lung cancer.
Shares Shanghai Henlius Biotech, Non-small-cell lung cancer.
Shares Shanghai Henlius Biotech, Non-small-cell lung cancer.
Shares Shanghai Henlius Biotech, Non-small-cell lung cancer.
Shares Shanghai Henlius Biotech, Non-small-cell lung cancer.
Shares Shanghai Henlius Biotech, Non-small-cell lung cancer.